scholarly journals Expression and Clinical Significance of Hypoxia-related Factors HIF-1a, Gli-1 and MMP9 in Breast Cancer

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Chen Hong ◽  
Donghong Xu ◽  
Haizhi Qiao ◽  
Jinmei Li ◽  
Jinku Zhang
Keyword(s):  
Breast Cancer ◽  
Clinical Significance ◽  
Ductal Carcinoma ◽  
Normal Breast ◽  
Carcinoma Of The Breast ◽  
Related Factors ◽  
Normal Tissues ◽  
Gli 1 ◽  
Cancer Tissues ◽  
Breast Tissues

Objective: To investigate the expression and clinical significance of hypoxia inducible factors HIF-1a, Gli-1 and MMP9 in breast cancer. Methods: Eighty patients with invasive ductal carcinoma of the breast and 40 normal tissues adjacent to cancer were selected. Immunohistochemical methods were used to detect the expression of HIF-1a, Gli-1 and MMP9 in breast cancer and normal tissues adjacent to cancer, and their relationship with clinicopathological features of breast cancer and prognosis was explored. Results: The positive rates of HIF-1a, Gli-1 and MMP9 in breast cancer tissues were significantly higher than those in normal breast tissues. HIF-1a, Gli-1 and MMP9 expressions are positively correlated in breast cancer. Conclusion: HIF-1a, Gli-1 and MMP9 proteins are involved in the pathogenesis of breast cancer.

scholarly journals The Expression and Clinical Significance of Sema4A in Triple Negative Breast Cancer

2020 ◽  
Vol 4 (6) ◽  
Author(s):  
Hong Chen ◽  
Chunhui Gao ◽  
Lingyan Wang ◽  
Wenming Zhao ◽  
Bingxin Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Significance ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Ductal Carcinoma ◽  
Clinicopathological Features ◽  
Carcinoma Of The Breast ◽  
Promote Cell Proliferation ◽  
Normal Tissues ◽  
Immunohistochemical Methods

Objectives: To explore the expression and clinical significance of Sema4A in triple-negative breast cancer. Methods: Eighty patients with invasive ductal carcinoma of the breast and 40 normal tissues adjacent to cancer were selected. Immunohistochemical methods were used to detect the expression of Sema4A in breast cancer and normal tissues adjacent to cancer, and its relationship with breast cancer clinicopathological features and prognosis. Results: The expression of Sema4a in the serum of BCA patients was significantly higher than that of healthy controls. In addition, the expression of sema4a in BCA cells and in the cell supernatants was also up-regulated under hypoxia. Conclusion: Exogenous Sema4A can protect BCA cells from hypoxia-induced cytotoxicity, inhibit cell apoptosis and promote cell proliferation.

scholarly journals The Differential Expression of Aqueous Soluble Proteins in Breast Normal and Cancerous Tissues in Relation to Ethnicity of the Patients; Chinese, Malay and Indian

2010 ◽  
Vol 28 (3) ◽  
pp. 149-165 ◽  
Author(s):  
Seng Liang ◽  
Manjit Singh ◽  
Lay-Harn Gam
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma ◽  
Protein Profile ◽  
Female Breast Cancer ◽  
Female Mortality ◽  
Normal Tissues ◽  
Infiltrating Ductal Carcinoma ◽  
Female Breast ◽  
Proteomic Approach ◽  
Breast Tissues

Female breast cancer is one of the leading causes of female mortality worldwide. In Malaysia, breast cancer is the most commonly diagnosed cancer in women. Of the women in Malaysia, the Chinese have the highest number of breast cancer cases, followed by the Indian and the Malay. The most common type of breast cancer is infiltrating ductal carcinoma (IDC). A proteomic approach was applied in this study to identify changes in the protein profile of cancerous tissues compared with normal tissues from 18 patients; 8 Chinese, 6 Malay and 4 Indian were analysed. Twenty-four differentially expressed hydrophilic proteins were identified. We evaluated the potential of these proteins as biomarkers for infiltrating ductal carcinoma based on their ethnic-specific expressions. Three of the upregulated proteins, calreticulin, 14-3-3 protein zeta and 14-3-3 protein eta, were found to be expressed at a significantly higher level in the cancerous breast tissues when compared with the normal tissues in cases of infiltrating ductal carcinoma. The upregulation in expression was particularly dominant in the Malay cohort.

scholarly journals Promoter Methylation Status of the Retinoic Acid Receptor-Beta 2 Gene in Breast Cancer Patients: A Case Control Study and Systematic Review

Breast Care ◽  
2019 ◽  
Vol 14 (2) ◽  
pp. 117-123 ◽  
Author(s):  
Kheirollah Yari ◽  
Zohreh Rahimi
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Retinoic Acid Receptor ◽  
Methylation Status ◽  
Normal Breast ◽  
Breast Cancer Patients ◽  
Retinoic Acid Receptor Beta ◽  
Cancer Tissues ◽  
Breast Tissues ◽  
Receptor Beta

Background: We aimed to determine the promoter methylation status of the retinoic acid receptor-beta 2 (RARβ2) gene among breast cancer patients and to review relevant studies in this field in various populations. Methods: We analyzed 400 samples which comprised blood specimens from 102 breast cancer patients, 102 first-degree female relatives of patients, 100 cancer-free females, 48 breast cancer tissues, and 48 adjacent normal breast tissues from the same patients. The RARβ2 methylation status was determined using methylation-specific polymerase chain reaction (MSP) and DNA sequencing methods. Results: The presence of combined partially methylated (MU) and fully methylated (MM) forms of the RARβ2 gene (MU+MM) in the blood of patients was associated with susceptibility to breast cancer (odds ratio = 4.7, p = 0.05). A significantly higher frequency of the MM genotype was observed in cancer tissue (10.4%) compared to matched adjacent normal breast tissue (0%) (p = 0.02). Conclusion: We found a higher frequency of RARβ2 gene methylation in the blood and cancer tissues of patients compared to the blood of controls and adjacent normal breast tissues. The survey of studies on various populations demonstrated a higher RARβ2 methylation frequency in breast cancer patients compared to normal individuals, and many reports suggest a significant association between hypermethylation of the gene and susceptibility to breast cancer.

scholarly journals Promoter Hypermethylation and Suppression of Glutathione Peroxidase 3 Are Associated with Inflammatory Breast Carcinogenesis

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Mona M. Mohamed ◽  
Salwa Sabet ◽  
Dun-Fa Peng ◽  
M. Akram Nouh ◽  
Mohamed El-Shinawi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Glutathione Peroxidase ◽  
Cancer Progression ◽  
Epigenetic Regulation ◽  
Ductal Carcinoma ◽  
Methylation Status ◽  
Promoter Hypermethylation ◽  
Normal Breast ◽  
Glutathione Peroxidase 3 ◽  
Breast Tissues

Reactive oxygen species (ROS) play a crucial role in breast cancer initiation, promotion, and progression. Inhibition of antioxidant enzymes that remove ROS was found to accelerate cancer growth. Studies showed that inhibition of glutathione peroxidase-3 (GPX3) was associated with cancer progression. Although the role of GPX3 has been studied in different cancer types, its role in breast cancer and its epigenetic regulation have not yet been investigated. The aim of the present study was to investigate GPX3 expression and epigenetic regulation in carcinoma tissues of breast cancer patients’ in comparison to normal breast tissues. Furthermore, we compared GPX3 level of expression and methylation status in aggressive phenotype inflammatory breast cancer (IBC) versus non-IBC invasive ductal carcinoma (IDC). We found that GPX3 mRNA and protein expression levels were downregulated in the carcinoma tissues of IBC compared to non-IBC. However, we did not detect significant correlation between GPX3 and patients’ clinical-pathological prosperities. Promoter hypermethylation of GPX3 gene was detected in carcinoma tissues not normal breast tissues. In addition, IBC carcinoma tissues showed a significant increase in the promoter hypermethylation of GPX3 gene compared to non-IBC. Our results propose that downregulation of GPX3 in IBC may play a role in the disease progression.

scholarly journals Immunohistochemiluminescence Detection: A Quantitative Tool in Breast Cancer HER-2 Status Evaluation

2013 ◽  
Vol 34 (5) ◽  
pp. 373-377 ◽  
Author(s):  
Moacyr Jesus Barreto de Melo Rêgo ◽  
Marina Ferraz Cordeiro ◽  
Carmelita de Lima Bezerra Cavalcanti ◽  
Luiz Bezerra de Carvalho Junior ◽  
Eduardo Isidoro Carneiro Beltrão
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma ◽  
Breast Tumors ◽  
Normal Breast ◽  
Normal Tissues ◽  
Breast Invasive Ductal Carcinoma ◽  
Her 2 ◽  
Status Differences ◽  
Quantitative Tool ◽  
Acridinium Ester

Her-2 status evaluation in breast cancer has prognostic and treatment response value but its interobserver variation among pathologists is a problem since it is not quantitatively assayed. This study presents an immunohistochemiluminescence method to quantify Her-2 in breast cancer. Anti-Her-2 antibody was conjugated to acridinium ester (AE) and used to evaluate/quantify Her-2 status in breast Invasive Ductal Carcinoma (IDC,n= 50) comparing with traditional immunohistochemistry. Anti-HER-2-AE results were expressed in Relative Lights Units (RLU) and showed to be able to distinguish and quantify the differences between the three groups of Her-2 status. 3+ Her-2 status presented the highest RLU (246,982 × 103± 2.061 × 103) compared to 2+ (76,146 × 103± 0.290 × 103), negative (27,415 × 103± 1.445 × 103) and normal tissues (27,064 × 103± 2.060). Status differences were significant between 3+ and 2+ (p= 0.0025); 2+ and negative (p= 0.0003), and +3 and +1 (p= 0.0001) beside this, normal breast control RLU was 27,064 × 103± 2,060 × 103, similar to negative cases. Results showed that anti-HER-2-AE conjugate was effective in breast tumors Her-2 status evaluation, allowing its quantitative establishment to consequently decrease the subjectivity in prognostic and predictive information intrinsic to this test.

scholarly journals Analysis of the prognostic significance of solute carrier (SLC) family 39 genes in breast cancer

2020 ◽  
Vol 40 (8) ◽  
Author(s):  
Limei Liu ◽  
Jiaomin Yang ◽  
Chao Wang
Keyword(s):  
Breast Cancer ◽  
Prognostic Significance ◽  
Normal Breast ◽  
Mrna Levels ◽  
Growth And Survival ◽  
Normal Tissues ◽  
Physiological Processes ◽  
Kaplan Meier ◽  
Solute Carrier ◽  
Breast Tissues

Abstract Background: Breast cancer (BC) is the most common malignancy in females and remains a main cause of cancer-associated death worldwide. The solute carrier (SLC) groups of membrane transport proteins, which control the influx of zinc, participate in ranging of physiological processes and may provide novel therapeutic targets of cancers. However, the prognostic values of individual SLC family 39 (SLC39A) genes in patients with BC are not clarified. Materials and Methods: The mRNA expression of SLC family 39 genes in BC was evaluated by using the UALCAN database. The prognostic values of overall survival (OS) of SLC family 39 genes in patients with BC were investigated by Kaplan–Meier plotter. The survival analysis of cells was determined by Project Achilles. Results: The analytic results suggested that SLC39A1, SLC39A3, SLC39A4, SLC39A5, SLC39A6, SLC39A7, SLC39A9, SLC39A10, SLC39A11 and SLC39A13 were significantly up-regulated in BC tissues compared with normal breast tissues. However, SLC39A8 and SLC39A14 were expressed higher in normal tissues than in BC tissues. High expression of SLC39A2, SLC39A3, SLC39A4, SLC39A5, SLC39A7, SLC39A12 and SLC39A13 was significantly associated with worse OS in patients with BC. In contrast, high mRNA levels of SLC39A6 and SLC39A14 indicated favorable OS. Through subgroup analysis, all abnormal expressed SLC family members were correlated with prognoses of patients with specific BC. Moreover, SLC39A7 was associated with proliferation and cloning of BC. Conclusions: Our results suggested that SLC family 39 members were promising prognostic biomarkers of BC. The SLC39A7 played a key role in growth and survival of BC cells.

scholarly journals Nuclear ING3 Expression Is Correlated With a Good Prognosis of Breast Cancer

2021 ◽  
Vol 10 ◽  
Author(s):  
Xiaoyan Wu ◽  
Chuang Chen ◽  
Bin Luo ◽  
Dandan Yan ◽  
Honglin Yan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cox Regression ◽  
Histological Grade ◽  
Normal Breast ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Positive Type ◽  
Cox Regression Analysis ◽  
Cancer Tissues ◽  
Breast Tissues

The inhibitor of growth (ING) family was discovered as the type II tumor suppressors, which regulated the proliferation, apoptosis, differentiation, angiogenesis, metastasis, and invasion of tumor cells through multiple pathways. ING3, a new member of ING family, has been reported to be downregulated in several types of tumors. However, few studies on ING3 in breast cancer have been reported. In this study, we investigated the expression of ING3 and determined its prognostic value in breast cancer. The immunohistochemistry was performed to evaluate the expression of ING3 in tissue microarrays (TMA) including breast cancer tissues (n=211) and normal breast tissues (n=50). In normal breast tissues, ING3 protein was detected in both the cytoplasm and nucleus. In breast cancer tissues, ING3 protein was principally detected in the cytoplasm. Compared with normal breast tissues, the expression of ING3 in nucleus was remarkably reduced in breast cancer tissues. The downregulated ING3 in nucleus was significantly correlated with clinicopathological characteristics including histological grade, lymph node metastasis, and the status of ER and PR. In HER2 positive-type and triple-negative breast cancer (TNBC) patients, it had the lower rate of nuclear ING3 with high expression than that in luminal-type. Moreover, Kaplan-Meier curves demonstrated that the reduced expression of ING3 in nucleus was correlated with a poorer 5-DFS and 5-OS of breast cancer patients. Importantly, multivariate Cox regression analysis suggested that the reduced expression of ING3 in nucleus was an independent prognostic factor in breast cancer. Our study comprehensively described the expression of ING3 in breast cancer for the first time and proved that it was an independent prognostic predictor of breast cancer, as well as a new idea for study of breast cancer.

Immunohistochemical Staining of Metastatic Ductal Carcinomas of the Breast by Monoclonal Antibodies used in Imaging and Therapy: A Comparative Study

1995 ◽  
Vol 10 (3) ◽  
pp. 129-135 ◽  
Author(s):  
L.P. Howell ◽  
S.J. Denardo ◽  
N.B. Levy ◽  
J. Lund ◽  
G.L. Denardo
Keyword(s):  
Breast Cancer ◽  
Monoclonal Antibodies ◽  
Immunohistochemical Staining ◽  
Tumor Tissue ◽  
Ductal Carcinoma ◽  
Immunoperoxidase Staining ◽  
Cancer Tissue ◽  
Carcinoma Of The Breast ◽  
Normal Tissues ◽  
Metastatic Lesions

Five monoclonal antibodies (MoAbs) (L6, 170H.82, 155, BrE-3 and BR96), most of which have been previously shown to target breast cancer and not normal tissues by immunoscintigraphic imaging, were evaluated for their frequency and pattern of immunohistochemical staining in 67 to 116 metastatic lesions from patients with ductal carcinoma of the breast. Immunoperoxidase staining in 75% or more of the cells occurred in 56/116 (48%) for L6, 44189 (49%) for Br, -96, 58/102 (57%) for 155, 62/99 (84%) for 170H.82, and 65.67 (97%) for BrE-3. With the first three MoAbs, an additional 6-10% of the tumors showed staining in 50-75% of tumor cells. These results illustrate that most patients with metastatic ductal carcinoma have cancer tissue in which a high percent of cells will react to several of these selected MoAbs that target different epitopes. The high expression of the MoAb targets throughout the tumor tissue makes these antibodies potential candidates to carry immunologically directed radioimmunotherapy and is an aid in selecting patients for treatment..

scholarly journals Over-Expression of Centromere Protein U Participates in the Malignant Neoplastic Progression of Breast Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Xiaomeng Hao ◽  
Yufan Qiu ◽  
Lixia Cao ◽  
Xiaonan Yang ◽  
Dongdong Zhou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Progression ◽  
Ductal Carcinoma ◽  
Neoplastic Progression ◽  
Targeting Therapy ◽  
Normal Tissues ◽  
Centromere Protein ◽  
Cancer Models ◽  
Cancer Tissues

The expression of Centromere Protein U (CENP-U) is closely related to tumor malignancy. Till now, the role of CENP-U in the malignant progression of breast cancer remains unclear. In this study, we found that CENP-U protein was highly expressed in the primary invasive breast cancer tissues compared to the paired adjacent histologically normal tissues and ductal carcinoma in situ (DCIS) tissues. After CENP-U was knocked down, the proliferation and colony-forming abilities of breast cancer cells were significantly suppressed, whereas the portion of apoptotic cells was increased. Meanwhile, the PI3K/AKT/NF-κB pathway was significantly inhibited. In vivo studies showed that, the inhibition of CENP-U repressed the tumor growth in orthotopic breast cancer models. Therefore, our study demonstrated that the CENP-U might act as an oncogene and promote breast cancer progression via activation of the PI3K/AKT/NF-κB pathway, which suggests a promising direction for targeting therapy in breast cancer.

Sign in / Sign up

Export Citation Format

Share Document